MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment...
MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Company Research
Source: GlobeNewswire
PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGRAAV-RPGR is the only XLRP treatment in development to be awarded PRIME designation LONDON and NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) designations to AAV-RPGR, MeiraGTx’s investigational gene therapy for the treatment of x-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene. MeiraGTx and Janssen Pharmaceuticals, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, are jointly developing AAV-RPGR as part of a broader collaboration to develop and commercialize gene therapies for the treatment of inherited retinal diseases. PRIME designation was granted based on clinical data from MeiraGTx an
Show less
Read more
Impact Snapshot
Event Time:
MGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTX alerts
High impacting MeiraGTx Holdings plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MGTX
News
- Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsPR Newswire
- MeiraGTx Holdings plc (NASDAQ: MGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $36.00 price target on the stock.MarketBeat
- MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know [Yahoo! Finance]Yahoo! Finance
- MeiraGTx Holdings plc (NASDAQ: MGTX) had its price target raised by analysts at Royal Bank of Canada from $9.00 to $11.00. They now have an "outperform" rating on the stock.MarketBeat
- MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business UpdatesGlobeNewswire
MGTX
Earnings
- 11/13/24 - Miss
MGTX
Sec Filings
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- 11/12/24 - Form SC
- MGTX's page on the SEC website